Nitric Oxide Donors Are a New Class of Anti-cancer Therapeutics for the Reversal of Resistance and Inhibition of Metastasis View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2010-04-08

AUTHORS

Benjamin Bonavida , Stavroula Baritaki , Sara Huerta-Yepez , Mario I. Vega , Ali R. Jazirehi , James Berenson

ABSTRACT

Several novel therapeutic strategies are currently being explored for the treatment of tumors that are refractory to conventional cytotoxic therapies. Further, therapies aimed at the prevention and treatment of metastasis are also being investigated in pre-clinical and clinical studies. Most of these novel therapeutics are aimed at targeting gene products that regulate resistance and metastasis and have yielded several FDA-approved drugs/antibodies for the treatment of specific cancers. Nitric oxide donors, such as nitroglycerine which has been approved for the treatment of cardiovascular diseases, have been examined for their potential role in the treatment of cancer. NO donor-induced anti-tumor activities have been documented in several in vitro and in vivo animal studies. In addition, nitroglycerine therapeutic application in cancer patients has been initiated. Depending on the level of NO released and sustained, it is well documented that high levels of NO are anti-tumorigenic due to their complex activities, such as inhibiting constitutively hyperactivated cell survival/anti-apoptotic pathways and leading to their ability to sensitize drug/immune-resistant tumor cells to apoptosis by cytotoxic drugs. In addition, inhibition of such survival pathways also leads to the regulation of gene products that participate in the epithelial to mesenchymal transition (EMT) and metastasis and result in the inhibition of metastasis. Hence, NO donors can exert simultaneously a multitude of anti-cancer activities, including enhancement of apoptotic stimuli, inhibition of metastasis, inhibition of angiogenesis, and inhibition of hypoxia, depending on the concentration of the NO donor and on the cancer type and stage. Therefore, while novel therapeutics are being tested for specific anti-tumor targeting effects, we suggest that activation of endogenous iNOS or exogenous NO donors can substitute a large number of specific agents and may be considered as universal anti-cancer therapeutics when used alone or in combination with subtoxic cytotoxic drugs. Thus, the development of a new generation of NO donors with minimal toxicity and higher anti-tumor efficacy is warranted for investigation in clinical trials in cancer patients More... »

PAGES

459-477

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-1-4419-1432-3_24

DOI

http://dx.doi.org/10.1007/978-1-4419-1432-3_24

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1053252251


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biological Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0601", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biochemistry and Cell Biology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Microbiology, Immunology and Molecular Genetics, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California at Los Angeles, Le Conte Avenue, 90095-1747, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.19006.3e", 
          "name": [
            "Department of Microbiology, Immunology and Molecular Genetics, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California at Los Angeles, Le Conte Avenue, 90095-1747, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bonavida", 
        "givenName": "Benjamin", 
        "id": "sg:person.014442031637.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014442031637.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Microbiology, Immunology and Molecular Genetics, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California at Los Angeles, Le Conte Avenue, 90095-1747, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.19006.3e", 
          "name": [
            "Department of Microbiology, Immunology and Molecular Genetics, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California at Los Angeles, Le Conte Avenue, 90095-1747, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Baritaki", 
        "givenName": "Stavroula", 
        "id": "sg:person.01237456423.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01237456423.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Unidad de Invastigacion en Enfarmeda des Oncologicas, Hospital Infantil de Mexico, Federico Gomez, Mexico City, Mexico", 
          "id": "http://www.grid.ac/institutes/grid.414757.4", 
          "name": [
            "Unidad de Invastigacion en Enfarmeda des Oncologicas, Hospital Infantil de Mexico, Federico Gomez, Mexico City, Mexico"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Huerta-Yepez", 
        "givenName": "Sara", 
        "id": "sg:person.01171343223.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171343223.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Unidad de Investigacion Medica En Inmunologia e Infactologia, Hospital de Infectologia. CMN \u201cLA Caza\u201d IMSS, Mexico City, Mexico", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Unidad de Investigacion Medica En Inmunologia e Infactologia, Hospital de Infectologia. CMN \u201cLA Caza\u201d IMSS, Mexico City, Mexico"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vega", 
        "givenName": "Mario I.", 
        "id": "sg:person.01123230023.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123230023.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Microbiology, Immunology and Molecular Genetics, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California at Los Angeles, Le Conte Avenue, 90095-1747, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.19006.3e", 
          "name": [
            "Department of Microbiology, Immunology and Molecular Genetics, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California at Los Angeles, Le Conte Avenue, 90095-1747, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jazirehi", 
        "givenName": "Ali R.", 
        "id": "sg:person.01016673065.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016673065.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hematology/Oncology, Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.418721.9", 
          "name": [
            "Hematology/Oncology, Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Berenson", 
        "givenName": "James", 
        "id": "sg:person.0722327074.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722327074.67"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2010-04-08", 
    "datePublishedReg": "2010-04-08", 
    "description": "Several novel therapeutic strategies are currently being explored for the treatment of tumors that are refractory to conventional cytotoxic therapies. Further, therapies aimed at the prevention and treatment of metastasis are also being investigated in pre-clinical and clinical studies. Most of these novel therapeutics are aimed at targeting gene products that regulate resistance and metastasis and have yielded several FDA-approved drugs/antibodies for the treatment of specific cancers. Nitric oxide donors, such as nitroglycerine which has been approved for the treatment of cardiovascular diseases, have been examined for their potential role in the treatment of cancer. NO donor-induced anti-tumor activities have been documented in several in vitro and in vivo animal studies. In addition, nitroglycerine therapeutic application in cancer patients has been initiated. Depending on the level of NO released and sustained, it is well documented that high levels of NO are anti-tumorigenic due to their complex activities, such as inhibiting constitutively hyperactivated cell survival/anti-apoptotic pathways and leading to their ability to sensitize drug/immune-resistant tumor cells to apoptosis by cytotoxic drugs. In addition, inhibition of such survival pathways also leads to the regulation of gene products that participate in the epithelial to mesenchymal transition (EMT) and metastasis and result in the inhibition of metastasis. Hence, NO donors can exert simultaneously a multitude of anti-cancer activities, including enhancement of apoptotic stimuli, inhibition of metastasis, inhibition of angiogenesis, and inhibition of hypoxia, depending on the concentration of the NO donor and on the cancer type and stage. Therefore, while novel therapeutics are being tested for specific anti-tumor targeting effects, we suggest that activation of endogenous iNOS or exogenous NO donors can substitute a large number of specific agents and may be considered as universal anti-cancer therapeutics when used alone or in combination with subtoxic cytotoxic drugs. Thus, the development of a new generation of NO donors with minimal toxicity and higher anti-tumor efficacy is warranted for investigation in clinical trials in cancer patients", 
    "editor": [
      {
        "familyName": "Bonavida", 
        "givenName": "Benjamin", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-1-4419-1432-3_24", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-1-4419-1431-6", 
        "978-1-4419-1432-3"
      ], 
      "name": "Nitric Oxide (NO) and Cancer", 
      "type": "Book"
    }, 
    "keywords": [
      "inhibition of metastasis", 
      "nitric oxide donor", 
      "oxide donor", 
      "cytotoxic drugs", 
      "immune-resistant tumor cells", 
      "NO donor", 
      "novel therapeutics", 
      "drugs/antibody", 
      "anti-cancer therapeutics", 
      "conventional cytotoxic therapy", 
      "treatment of metastases", 
      "novel therapeutic strategies", 
      "anti-tumor efficacy", 
      "higher anti-tumor efficacy", 
      "anti-tumor activity", 
      "reversal of resistance", 
      "inhibition of angiogenesis", 
      "inhibition of hypoxia", 
      "levels of NO", 
      "exogenous NO donor", 
      "treatment of tumors", 
      "vivo animal studies", 
      "anti-apoptotic pathways", 
      "endogenous iNOS", 
      "anti-cancer activity", 
      "treatment of cancer", 
      "cytotoxic therapy", 
      "cancer patients", 
      "clinical trials", 
      "clinical studies", 
      "cardiovascular disease", 
      "therapeutic strategies", 
      "animal studies", 
      "metastasis", 
      "specific cancers", 
      "mesenchymal transition", 
      "cancer types", 
      "tumor cells", 
      "minimal toxicity", 
      "specific agents", 
      "survival pathways", 
      "potential role", 
      "treatment", 
      "therapy", 
      "inhibition", 
      "therapeutics", 
      "cancer", 
      "drugs", 
      "therapeutic applications", 
      "gene products", 
      "donors", 
      "high levels", 
      "patients", 
      "tumors", 
      "pathway", 
      "disease", 
      "nitroglycerine", 
      "activity", 
      "hypoxia", 
      "trials", 
      "prevention", 
      "antibodies", 
      "angiogenesis", 
      "efficacy", 
      "apoptotic stimuli", 
      "FDA", 
      "iNO", 
      "levels", 
      "apoptosis", 
      "study", 
      "complex activity", 
      "toxicity", 
      "activation", 
      "resistance", 
      "cells", 
      "stimuli", 
      "agents", 
      "addition", 
      "role", 
      "regulation", 
      "reversal", 
      "effect", 
      "large number", 
      "concentration", 
      "stage", 
      "combination", 
      "ability", 
      "NO", 
      "development", 
      "new class", 
      "strategies", 
      "number", 
      "types", 
      "investigation", 
      "multitude", 
      "products", 
      "new generation", 
      "enhancement", 
      "generation", 
      "class", 
      "applications", 
      "transition"
    ], 
    "name": "Nitric Oxide Donors Are a New Class of Anti-cancer Therapeutics for the Reversal of Resistance and Inhibition of Metastasis", 
    "pagination": "459-477", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1053252251"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-1-4419-1432-3_24"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-1-4419-1432-3_24", 
      "https://app.dimensions.ai/details/publication/pub.1053252251"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-06-01T22:27", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220601/entities/gbq_results/chapter/chapter_102.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-1-4419-1432-3_24"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-1-4419-1432-3_24'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-1-4419-1432-3_24'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-1-4419-1432-3_24'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-1-4419-1432-3_24'


 

This table displays all metadata directly associated to this object as RDF triples.

214 TRIPLES      23 PREDICATES      129 URIs      120 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-1-4419-1432-3_24 schema:about anzsrc-for:06
2 anzsrc-for:0601
3 anzsrc-for:11
4 anzsrc-for:1112
5 schema:author N7816b35c397846f28fb7815a88c69794
6 schema:datePublished 2010-04-08
7 schema:datePublishedReg 2010-04-08
8 schema:description Several novel therapeutic strategies are currently being explored for the treatment of tumors that are refractory to conventional cytotoxic therapies. Further, therapies aimed at the prevention and treatment of metastasis are also being investigated in pre-clinical and clinical studies. Most of these novel therapeutics are aimed at targeting gene products that regulate resistance and metastasis and have yielded several FDA-approved drugs/antibodies for the treatment of specific cancers. Nitric oxide donors, such as nitroglycerine which has been approved for the treatment of cardiovascular diseases, have been examined for their potential role in the treatment of cancer. NO donor-induced anti-tumor activities have been documented in several in vitro and in vivo animal studies. In addition, nitroglycerine therapeutic application in cancer patients has been initiated. Depending on the level of NO released and sustained, it is well documented that high levels of NO are anti-tumorigenic due to their complex activities, such as inhibiting constitutively hyperactivated cell survival/anti-apoptotic pathways and leading to their ability to sensitize drug/immune-resistant tumor cells to apoptosis by cytotoxic drugs. In addition, inhibition of such survival pathways also leads to the regulation of gene products that participate in the epithelial to mesenchymal transition (EMT) and metastasis and result in the inhibition of metastasis. Hence, NO donors can exert simultaneously a multitude of anti-cancer activities, including enhancement of apoptotic stimuli, inhibition of metastasis, inhibition of angiogenesis, and inhibition of hypoxia, depending on the concentration of the NO donor and on the cancer type and stage. Therefore, while novel therapeutics are being tested for specific anti-tumor targeting effects, we suggest that activation of endogenous iNOS or exogenous NO donors can substitute a large number of specific agents and may be considered as universal anti-cancer therapeutics when used alone or in combination with subtoxic cytotoxic drugs. Thus, the development of a new generation of NO donors with minimal toxicity and higher anti-tumor efficacy is warranted for investigation in clinical trials in cancer patients
9 schema:editor Ne896be8b24524102a46e4fd5fe833420
10 schema:genre chapter
11 schema:inLanguage en
12 schema:isAccessibleForFree false
13 schema:isPartOf N4ebba44bf228498cb99ef9a61b6322ab
14 schema:keywords FDA
15 NO
16 NO donor
17 ability
18 activation
19 activity
20 addition
21 agents
22 angiogenesis
23 animal studies
24 anti-apoptotic pathways
25 anti-cancer activity
26 anti-cancer therapeutics
27 anti-tumor activity
28 anti-tumor efficacy
29 antibodies
30 apoptosis
31 apoptotic stimuli
32 applications
33 cancer
34 cancer patients
35 cancer types
36 cardiovascular disease
37 cells
38 class
39 clinical studies
40 clinical trials
41 combination
42 complex activity
43 concentration
44 conventional cytotoxic therapy
45 cytotoxic drugs
46 cytotoxic therapy
47 development
48 disease
49 donors
50 drugs
51 drugs/antibody
52 effect
53 efficacy
54 endogenous iNOS
55 enhancement
56 exogenous NO donor
57 gene products
58 generation
59 high levels
60 higher anti-tumor efficacy
61 hypoxia
62 iNO
63 immune-resistant tumor cells
64 inhibition
65 inhibition of angiogenesis
66 inhibition of hypoxia
67 inhibition of metastasis
68 investigation
69 large number
70 levels
71 levels of NO
72 mesenchymal transition
73 metastasis
74 minimal toxicity
75 multitude
76 new class
77 new generation
78 nitric oxide donor
79 nitroglycerine
80 novel therapeutic strategies
81 novel therapeutics
82 number
83 oxide donor
84 pathway
85 patients
86 potential role
87 prevention
88 products
89 regulation
90 resistance
91 reversal
92 reversal of resistance
93 role
94 specific agents
95 specific cancers
96 stage
97 stimuli
98 strategies
99 study
100 survival pathways
101 therapeutic applications
102 therapeutic strategies
103 therapeutics
104 therapy
105 toxicity
106 transition
107 treatment
108 treatment of cancer
109 treatment of metastases
110 treatment of tumors
111 trials
112 tumor cells
113 tumors
114 types
115 vivo animal studies
116 schema:name Nitric Oxide Donors Are a New Class of Anti-cancer Therapeutics for the Reversal of Resistance and Inhibition of Metastasis
117 schema:pagination 459-477
118 schema:productId Nc06e8f31f6cf418888c25cb18e86cc25
119 Nc387d608686d4f72969fb18bdba32fe5
120 schema:publisher N04281dc376d44220831fad1fc08e0d60
121 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053252251
122 https://doi.org/10.1007/978-1-4419-1432-3_24
123 schema:sdDatePublished 2022-06-01T22:27
124 schema:sdLicense https://scigraph.springernature.com/explorer/license/
125 schema:sdPublisher Ne4e652603fa0405a89bfc803e0cd8630
126 schema:url https://doi.org/10.1007/978-1-4419-1432-3_24
127 sgo:license sg:explorer/license/
128 sgo:sdDataset chapters
129 rdf:type schema:Chapter
130 N04281dc376d44220831fad1fc08e0d60 schema:name Springer Nature
131 rdf:type schema:Organisation
132 N17442d22ca4e488ab27a302b4aed751a rdf:first sg:person.01237456423.01
133 rdf:rest N9da03c31251a44758fb5e0765a4a5acb
134 N2283d9c411a9453fbe21c34a2bfe5a19 rdf:first sg:person.01016673065.20
135 rdf:rest N6e559c13747440d88b8a959dc6f368d4
136 N4ebba44bf228498cb99ef9a61b6322ab schema:isbn 978-1-4419-1431-6
137 978-1-4419-1432-3
138 schema:name Nitric Oxide (NO) and Cancer
139 rdf:type schema:Book
140 N6e559c13747440d88b8a959dc6f368d4 rdf:first sg:person.0722327074.67
141 rdf:rest rdf:nil
142 N7816b35c397846f28fb7815a88c69794 rdf:first sg:person.014442031637.81
143 rdf:rest N17442d22ca4e488ab27a302b4aed751a
144 N9da03c31251a44758fb5e0765a4a5acb rdf:first sg:person.01171343223.95
145 rdf:rest Nb8966fdbd8c54f798c33c0c7744aef98
146 Nb8966fdbd8c54f798c33c0c7744aef98 rdf:first sg:person.01123230023.51
147 rdf:rest N2283d9c411a9453fbe21c34a2bfe5a19
148 Nc06e8f31f6cf418888c25cb18e86cc25 schema:name dimensions_id
149 schema:value pub.1053252251
150 rdf:type schema:PropertyValue
151 Nc387d608686d4f72969fb18bdba32fe5 schema:name doi
152 schema:value 10.1007/978-1-4419-1432-3_24
153 rdf:type schema:PropertyValue
154 Ne4e652603fa0405a89bfc803e0cd8630 schema:name Springer Nature - SN SciGraph project
155 rdf:type schema:Organization
156 Ne7b0385cfbf0436b9af953e98eb0c5c6 schema:familyName Bonavida
157 schema:givenName Benjamin
158 rdf:type schema:Person
159 Ne896be8b24524102a46e4fd5fe833420 rdf:first Ne7b0385cfbf0436b9af953e98eb0c5c6
160 rdf:rest rdf:nil
161 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
162 schema:name Biological Sciences
163 rdf:type schema:DefinedTerm
164 anzsrc-for:0601 schema:inDefinedTermSet anzsrc-for:
165 schema:name Biochemistry and Cell Biology
166 rdf:type schema:DefinedTerm
167 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
168 schema:name Medical and Health Sciences
169 rdf:type schema:DefinedTerm
170 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
171 schema:name Oncology and Carcinogenesis
172 rdf:type schema:DefinedTerm
173 sg:person.01016673065.20 schema:affiliation grid-institutes:grid.19006.3e
174 schema:familyName Jazirehi
175 schema:givenName Ali R.
176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016673065.20
177 rdf:type schema:Person
178 sg:person.01123230023.51 schema:affiliation grid-institutes:None
179 schema:familyName Vega
180 schema:givenName Mario I.
181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123230023.51
182 rdf:type schema:Person
183 sg:person.01171343223.95 schema:affiliation grid-institutes:grid.414757.4
184 schema:familyName Huerta-Yepez
185 schema:givenName Sara
186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171343223.95
187 rdf:type schema:Person
188 sg:person.01237456423.01 schema:affiliation grid-institutes:grid.19006.3e
189 schema:familyName Baritaki
190 schema:givenName Stavroula
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01237456423.01
192 rdf:type schema:Person
193 sg:person.014442031637.81 schema:affiliation grid-institutes:grid.19006.3e
194 schema:familyName Bonavida
195 schema:givenName Benjamin
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014442031637.81
197 rdf:type schema:Person
198 sg:person.0722327074.67 schema:affiliation grid-institutes:grid.418721.9
199 schema:familyName Berenson
200 schema:givenName James
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722327074.67
202 rdf:type schema:Person
203 grid-institutes:None schema:alternateName Unidad de Investigacion Medica En Inmunologia e Infactologia, Hospital de Infectologia. CMN “LA Caza” IMSS, Mexico City, Mexico
204 schema:name Unidad de Investigacion Medica En Inmunologia e Infactologia, Hospital de Infectologia. CMN “LA Caza” IMSS, Mexico City, Mexico
205 rdf:type schema:Organization
206 grid-institutes:grid.19006.3e schema:alternateName Department of Microbiology, Immunology and Molecular Genetics, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California at Los Angeles, Le Conte Avenue, 90095-1747, Los Angeles, CA, USA
207 schema:name Department of Microbiology, Immunology and Molecular Genetics, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California at Los Angeles, Le Conte Avenue, 90095-1747, Los Angeles, CA, USA
208 rdf:type schema:Organization
209 grid-institutes:grid.414757.4 schema:alternateName Unidad de Invastigacion en Enfarmeda des Oncologicas, Hospital Infantil de Mexico, Federico Gomez, Mexico City, Mexico
210 schema:name Unidad de Invastigacion en Enfarmeda des Oncologicas, Hospital Infantil de Mexico, Federico Gomez, Mexico City, Mexico
211 rdf:type schema:Organization
212 grid-institutes:grid.418721.9 schema:alternateName Hematology/Oncology, Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, USA
213 schema:name Hematology/Oncology, Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, USA
214 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...